Interferon therapy reduces the risk for hepatocellular carcinoma.
作者信息
Brown J L
机构信息
Cranfield University Postgraduate Medical School in Gloucester, Gloucestershire Royal Hospital, Gloucester GL1 3NN, UK.
出版信息
Gut. 2000 Nov;47(5):610-1. doi: 10.1136/gut.47.5.610.
Abstract
摘要
相似文献
1
Interferon therapy reduces the risk for hepatocellular carcinoma.干扰素治疗可降低肝细胞癌的风险。
Gut. 2000 Nov;47(5):610-1. doi: 10.1136/gut.47.5.610.
2
Hepatitis C and interferon: fewer cases of liver cancer.丙型肝炎与干扰素：肝癌病例减少
Prescrire Int. 2013 Jul;22(140):191.
3
Current status of antiviral therapy for chronic hepatitis C.慢性丙型肝炎抗病毒治疗的现状
Adv Exp Med Biol. 1999;458:29-37. doi: 10.1007/978-1-4615-4743-3_4.
4
[Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].[干扰素治疗对丙型肝炎病毒阳性肝硬化患者肝细胞癌发生率的影响]
Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):600-4.
5
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C?干扰素疗法能否预防慢性丙型肝炎患者发生肝细胞癌？
Gastroenterology. 1999 Sep;117(3):738-9. doi: 10.1016/s0016-5085(99)70471-3.
6
7
Management of chronic hepatitis C and prevention of hepatocellular carcinoma.慢性丙型肝炎的管理与肝细胞癌的预防
J Gastroenterol. 2002;37 Suppl 13:69-73. doi: 10.1007/BF02990103.
8
Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.干扰素治疗对降低丙型慢性肝炎患者肝细胞癌发病率的有效性。
J Epidemiol. 2000 Jul;10(4):234-40. doi: 10.2188/jea.10.234.
9
[Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].慢性丙型肝炎患者抗病毒治疗预防肝细胞癌的成本效益
Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):511-4.
10
Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.干扰素诱导的长期生化反应可降低丙型肝炎病毒感染中的肝癌发生。
J Med Virol. 2007 Oct;79(10):1485-90. doi: 10.1002/jmv.20925.
引用本文的文献
1
Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma.病毒性肝炎的治疗作为肝细胞癌的二级预防。
Cells. 2021 Nov 9;10(11):3091. doi: 10.3390/cells10113091.
2
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.直接作用抗病毒治疗丙型肝炎病毒后发生的肝细胞癌：临近尾声的争议。
World J Gastroenterol. 2020 Nov 21;26(43):6770-6781. doi: 10.3748/wjg.v26.i43.6770.
3
No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis.直接作用抗病毒治疗后肝细胞癌发生率更高的证据不足：一项荟萃分析。
Hepatoma Res. 2019;5. doi: 10.20517/2394-5079.2019.19. Epub 2019 Aug 7.
4
Nitazoxanide for chronic hepatitis C.硝唑尼特用于慢性丙型肝炎
Cochrane Database Syst Rev. 2014 Apr 6;2014(4):CD009182. doi: 10.1002/14651858.CD009182.pub2.
本文引用的文献
1
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.丙型肝炎病毒相关肝硬化：肝细胞癌发生及死亡时间
Gut. 2000 Jul;47(1):131-6. doi: 10.1136/gut.47.1.131.
2
45-year follow-up of hepatitis C virus infection in healthy young adults.健康年轻成年人丙型肝炎病毒感染的45年随访
Ann Intern Med. 2000 Jan 18;132(2):105-11. doi: 10.7326/0003-4819-132-2-200001180-00003.
3
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.丙型肝炎病毒相关性肝硬化的治疗：干扰素α-2b与不治疗的随机对照试验。
Hepatology. 1999 Jun;29(6):1870-5. doi: 10.1002/hep.510290616.
4
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.慢性丙型肝炎患者中干扰素治疗与肝细胞癌的关系。大阪肝细胞癌预防研究组。
Ann Intern Med. 1998 Jul 15;129(2):94-9. doi: 10.7326/0003-4819-129-2-199807150-00005.
5
Determinants of outcome of compensated hepatitis C virus-related cirrhosis.代偿期丙型肝炎病毒相关性肝硬化的预后决定因素
Hepatology. 1998 May;27(5):1435-40. doi: 10.1002/hep.510270535.
6
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.慢性丙型肝炎患者肝细胞癌的危险因素及其干扰素治疗后的发病率。大阪肝病研究小组。
Hepatology. 1998 May;27(5):1394-402. doi: 10.1002/hep.510270529.
7
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.丙型代偿期肝硬化的发病率和死亡率：384例患者的回顾性随访研究
Gastroenterology. 1997 Feb;112(2):463-72. doi: 10.1053/gast.1997.v112.pm9024300.
8
Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.α干扰素治疗可能预防丙型肝炎病毒相关肝硬化中的肝细胞癌。
J Hepatol. 1996 Feb;24(2):141-7. doi: 10.1016/s0168-8278(96)80022-5.
9
Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.干扰素α对伴有肝硬化的慢性活动性丙型肝炎患者肝细胞癌发生率影响的随机试验
Lancet. 1995 Oct 21;346(8982):1051-5. doi: 10.1016/s0140-6736(95)91739-x.
Zotero 插件